Version history

{
  "description": "The abstract reports that disease mutations phenocopy TDP-43 knockout effects on mRNA localization, suggesting a loss-of-function mechanism. However, this contradicts evidence that ALS mutations often cause toxic gain-of-function, requiring mechanistic clarification for therapeutic targeting.\n\nGap type: contradiction\nSource paper: TDP-43 directly inhibits mRNA accumulation in neurites through modulation of mRNA stability. (2026, The EMBO journal, PMID:41398473)",
  "domain": "neurodegeneration",
  "status": "resolved",
  "priority_score": 0.87,
  "importance_score": 0.89,
  "tractability_score": 0.82,
  "source": "pubmed:41398473",
  "evidence_summary": "Resolved by hypothesis h-ccc05373: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance. Score: 0.879. Supporting PMIDs: 39817908, NCT05869669, 39817908, NCT05869669, 39817908.",
  "resolution_criteria": "Resolution requires: (1) mRNA localization assay (RNA FISH, subcellular fractionation) in motor neurons from ALS-linked TDP-43 mutation carriers vs sporadic ALS vs controls, quantifying nuclear vs cytoplasmic TDP-43 ratio; (2) comparison with C9orf72 DPR/GR models establishing whether convergence on mislocalization is TDP-43-dependent or independent; (3) rescue experiment where restoring TDP-43 nuclear import reverses mislocalization in patient-derived motor neurons. Descriptive studies without rescue are insufficient.",
  "market_price": 0.5
}